Poland· PL-100527315

Austedo

A deutetrabenazine product containing deutetrabenazyna, registered in Poland by TEVA GmbH. The same ATC class is registered in 9 of our 19 countries.

ATC N07XX16

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAustedoATCN07XX16REGISTER NO.PL-100527315PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Deutetrabenazine is registered in 9 of 19 countries.

Countries holding a registration under ATC N07XX16 (deutetrabenazine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose

Deutetrabenazine · ATC N07XX16

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Deutetrabenazyna
Manufacturer
TEVA GmbH
Country
Poland (PL)
ATC code
N07XX16
ATC class
Deutetrabenazine
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991587376
  • gtin
    05909991587383

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

219 interactions on record for deutetrabenazine.

Graded by severity as the source publishes them — 53 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Deutetrabenazine · interactions on record

219 records

  • 53 severe
  • 164 moderate
  • 2 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • MetoclopramideA03FA01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Deutetrabenazine in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deutetrabenazine products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Austedo
  • Iceland · Austedo
  • Liechtenstein · Austedo
  • Norway · Austedo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/20baaf23-c14c-4de5-a2d3-4bbafa54fd02
GET /v1/drugs/20baaf23-c14c-4de5-a2d3-4bbafa54fd02?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki o przedłużonym uwalnianiu",
  "source": "urpl",
  "strength": "48 mg",
  "packaging": "05909991587376 ¦ Rpz ¦ EU/1/25/1956/010 ¦ 164347\n28 tabl.\n05909991587383 ¦ Rpz ¦ EU/1/25/1956/011 ¦ 164348\n84 tabl.",
  "substance": "Deutetrabenazyna 48 mg",
  "common_name": "Deutetrabenazyna",
  "pl_product_id": "100527315",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about deutetrabenazine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.